Suppr超能文献

大麻素与阿片类药物的相互作用:对阿片类药物依赖和戒断的影响。

Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal.

机构信息

Department of Neuroscience, Farber Institute for Neurosciences, Thomas Jefferson University, Philadelphia, PA 19107, USA.

出版信息

Neuroscience. 2013 Sep 17;248:637-54. doi: 10.1016/j.neuroscience.2013.04.034. Epub 2013 Apr 24.

Abstract

Withdrawal from opiates, such as heroin or oral narcotics, is characterized by a host of aversive physical and emotional symptoms. High rates of relapse and limited treatment success rates for opiate addiction have prompted a search for new approaches. For many opiate addicts, achieving abstinence may be further complicated by poly-drug use and co-morbid mental disorders. Research over the past decade has shed light on the influence of endocannabinoids (ECs) on the opioid system. Evidence from both animal and clinical studies point toward an interaction between these two systems, and suggest that targeting the EC system may provide novel interventions for managing opiate dependence and withdrawal. This review will summarize the literature surrounding the molecular effects of cannabinoids and opioids on the locus coeruleus-norepinephrine system, a key circuit implicated in the negative sequelae of opiate addiction. A consideration of the trends and effects of marijuana use in those seeking treatment to abstain from opiates in the clinical setting will also be presented. In summary, the present review details how cannabinoid-opioid interactions may inform novel interventions in the management of opiate dependence and withdrawal.

摘要

阿片类物质(如海洛因或口服麻醉品)戒断的特征是一系列令人不快的身体和情绪症状。阿片类药物成瘾的高复发率和有限的治疗成功率促使人们寻求新的方法。对于许多阿片类药物成瘾者来说,多药物使用和合并精神障碍可能使他们更难达到戒毒。过去十年的研究揭示了内源性大麻素(ECs)对阿片系统的影响。来自动物和临床研究的证据表明这两个系统之间存在相互作用,并表明针对 EC 系统可能为管理阿片类药物依赖和戒断提供新的干预措施。这篇综述将总结围绕大麻素和阿片类药物对蓝斑-去甲肾上腺素系统的分子作用的文献,蓝斑-去甲肾上腺素系统是一个关键的回路,与阿片类药物成瘾的负面后果有关。还将考虑在临床环境中寻求戒除阿片类药物的患者中使用大麻的趋势和影响。总之,本综述详细介绍了大麻素-阿片类药物相互作用如何为阿片类药物依赖和戒断的管理提供新的干预措施。

相似文献

1
Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal.
Neuroscience. 2013 Sep 17;248:637-54. doi: 10.1016/j.neuroscience.2013.04.034. Epub 2013 Apr 24.
3
The locus coeruleus: A key nucleus where stress and opioids intersect to mediate vulnerability to opiate abuse.
Brain Res. 2010 Feb 16;1314:162-74. doi: 10.1016/j.brainres.2009.09.036. Epub 2009 Sep 16.
5
Neuroadaptive responses in brainstem noradrenergic nuclei following chronic morphine exposure.
Mol Neurobiol. 2001 Apr-Jun;23(2-3):155-71. doi: 10.1385/mn:23:2-3:155.
7
Role of orexin type-1 receptors in paragiganto-coerulear modulation of opioid withdrawal and tolerance: A site specific focus.
Neuropharmacology. 2017 Nov;126:25-37. doi: 10.1016/j.neuropharm.2017.08.024. Epub 2017 Aug 18.
9
Advances in the field of cannabinoid--opioid cross-talk.
Addict Biol. 2008 Jun;13(2):213-24. doi: 10.1111/j.1369-1600.2008.00107.x.
10
Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice.
Science. 1999 Jan 15;283(5400):401-4. doi: 10.1126/science.283.5400.401.

引用本文的文献

3
Involvement of CB1R and CB2R Ligands in Sleep Disorders and Addictive Behaviors in the Last 25 Years.
Pharmaceuticals (Basel). 2025 Feb 18;18(2):266. doi: 10.3390/ph18020266.
4
Cannabinoids and General Anesthetics: Revisiting Molecular Mechanisms of Their Pharmacological Interactions.
Anesth Analg. 2024 Nov 6;140(6):1401-13. doi: 10.1213/ANE.0000000000007313.
7
The Role of Medicinal Cannabis as an Emerging Therapy for Opioid Use Disorder.
Pain Ther. 2024 Jun;13(3):435-455. doi: 10.1007/s40122-024-00599-1. Epub 2024 Apr 27.
8
Effects of CB1 receptor negative allosteric modulator Org27569 on oxycodone withdrawal symptoms in mice.
Psychopharmacology (Berl). 2024 Aug;241(8):1705-1717. doi: 10.1007/s00213-024-06591-z. Epub 2024 Apr 27.
9
Does cannabis use substitute for opioids? A preliminary exploratory survey in opioid maintenance patients.
Eur Arch Psychiatry Clin Neurosci. 2025 Mar;275(2):565-572. doi: 10.1007/s00406-023-01718-3. Epub 2024 Mar 19.
10
The Therapeutic Potential of Cannabidiol in Revolutionising Opioid Use Disorder Management.
Cureus. 2023 Dec 16;15(12):e50634. doi: 10.7759/cureus.50634. eCollection 2023 Dec.

本文引用的文献

1
Impact of cannabis use during stabilization on methadone maintenance treatment.
Am J Addict. 2013 Jul-Aug;22(4):344-51. doi: 10.1111/j.1521-0391.2013.12044.x.
2
Stress-induced sensitization of cortical adrenergic receptors following a history of cannabinoid exposure.
Exp Neurol. 2012 Aug;236(2):327-35. doi: 10.1016/j.expneurol.2012.05.016. Epub 2012 Jun 4.
3
Direct intra-accumbal infusion of a beta-adrenergic receptor antagonist abolishes WIN 55,212-2-induced aversion.
Neurosci Lett. 2011 Aug 1;500(1):82-5. doi: 10.1016/j.neulet.2011.06.008. Epub 2011 Jun 15.
4
Type I cannabinoid receptor trafficking: all roads lead to lysosome.
Traffic. 2011 Jan;12(1):12-8. doi: 10.1111/j.1600-0854.2010.01130.x. Epub 2010 Nov 3.
5
Medical marijuana 2010: it's time to fix the regulatory vacuum.
J Law Med Ethics. 2010 Fall;38(3):654-66. doi: 10.1111/j.1748-720X.2010.00519.x.
6
The multiplicity of action of cannabinoids: implications for treating neurodegeneration.
CNS Neurosci Ther. 2011 Dec;17(6):637-44. doi: 10.1111/j.1755-5949.2010.00195.x. Epub 2010 Sep 28.
7
Increased abundance of opioid receptor heteromers after chronic morphine administration.
Sci Signal. 2010 Jul 20;3(131):ra54. doi: 10.1126/scisignal.2000807.
8
Contribution of limbic norepinephrine to cannabinoid-induced aversion.
Psychopharmacology (Berl). 2010 Sep;211(4):479-91. doi: 10.1007/s00213-010-1923-7. Epub 2010 Jul 3.
9
Differential substance abuse patterns distribute according to gender in heroin addicts.
J Psychoactive Drugs. 2010 Mar;42(1):89-95. doi: 10.1080/02791072.2010.10399789.
10
Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders.
CNS Neurosci Ther. 2010 Jun;16(3):e72-91. doi: 10.1111/j.1755-5949.2010.00144.x. Epub 2010 Apr 12.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验